Power Nickel Inc (TSX-V:PNPN) has raised C$4,192,500 after completing an over-subscribed private placement of 13,750,000 flow-through (FT) units at a price of $0.20 per FT unit and 14,425,000 non-flow-through (NFT) units at a price of $0.10 per NFT unit.
In a statement, CEO Terry Lynch said: “With the new financing we have expanded our drill program and now plan to keep drilling through mid-December and start up again in mid-January.”
Endeavour Mining PLC (LSE:EDV, TSX:EDV, OTCQX:EDVMF) is still a “top pick” among senior gold producers of analysts at Canaccord Genuity (TSX:CF, LSE:CF) after the company announced an initial three-million-ounce resource at its Tanda-Iguela project in Côte D’Ivoire.
The firm reiterated a Buy rating and a price target of C$40. Endeavour shares traded 1% higher at $27.42 Tuesday morning.
Nextech AR Solutions Corp. (CSE:NTAR, OTCQB:NEXCF) said its subsidiary Map D has signed 25 new contracts so far this month, and hired several key executives as it positions itself for triple digit growth in 2023.
Map D is an event technology company that uses augmented reality (AR) and extended reality (XR) experiences, which is becoming an integral part of the Nextech Event Solutions brand.
G Mining Ventures Corp (TSX-V:GMIN, OTCQX:GMINF) has announced that its 100%-owned Tocantinzinho (TZ) Gold Project currently under construction in the state of Pará in Brazil remains on track and on budget for commercial production in the second half of 2024.
"Since making the formal construction decision in September, we have continued to make excellent progress on all fronts on our TZ project,” G Mining president and CEO Louis-Pierre Gignac said in a progress update.
Group Eleven Resources Corp (TSX-V:ZNG) has announced the start of a follow-up drill program stepping out from the recently announced discovery hole at its Ballywire zinc prospect of the PG West Project in Ireland.
The company said mobilization has begun on the previously-announced follow-up program at Ballywire, consisting of an initial five holes totalling approximately 1,500 metres (m).
Aftermath Silver (TSX-V:AAG) said it has closed its previously announced non-brokered private placement with the issuance of 24,385,666 units at a price of $0.17 each for gross proceeds of $4,145,563.
The company said it intends to use the proceeds of the private placement for funding preliminary economic assessments at its silver exploration projects and for working capital and general corporate purposes.
Condor Gold PLC (AIM:CNR, TSX:COG, OTC:CNDGF) said it has appointed Hannam and Partners to seek a buyer for the assets of the company. Condor recently completed a bankable feasibility study on the La India open-pit gold project in Nicaragua.
"Condor Gold has de-risked the La India gold project to a near construction-ready status, with an 18-month construction period from receipt of project financing,” said Mark Child, chief executive of Condor Gold in a statement.
Skye Bioscience Inc (OTCQB:SKYE) has announced that it will present a corporate overview at the RHK 2022 Disruptive Growth Conference being held December 5-6, 2022, at the offices of Reed Smith in New York City. Punit Dhillon, the company's chief executive officer and chair, will present on Monday, December 5, 2022, at 2.00pm ET. Dhillon and other representatives from the company will also be available for one-on-one meetings at the conference. The presentation will be available via webcast and archived in the News & Events section of Skye's investor relations website for a period of 90 days. Interested parties can register to watch the virtual presentation via the following link: https://wsw.com/webcast/rhk2/register.aspx?conf=rhk2&page=skye&url=https://wsw.com/webcast/rhk2/skye/1620612
Numinus Wellness Inc. (TSX:NUMI, OTC:LKYSF) has announced that Payton Nyquvest, its founder and CEO, will participate in a Water Tower Research Fireside Chat on Thursday, December 8, 2022, at 11.00am ET / 8.00am PT. The discussion will focus on key takeaways from Numinus' Q4 and Year End 2022 Results, including contributions from the acquisition of Novamind; expectations for 2023 and beyond; and upcoming catalysts for Numinus. Investors and other persons interested in participating, can register via the following link: https://us06web.zoom.us/webinar/register/WN_uEg8uOG9SXmpX2z-EyeDeQ. For more information about the event, or to schedule a one-on-one meeting with Numinus' management, interested parties can send an email to invest@numinus.com.
New Pacific Metals (TSX:NUAG, NYSE:NEWP) announced it has filed a technical report entitled "Carangas Project Technical Report" with an effective date of June 16, 2022.A copy of the Technical Report is available under the company's profile on SEDAR at www.sedar.com, on Edgar at www.sec.gov, and on the company's website at www.newpacificmetals.com.
Outlook Therapeutics Inc (NASDAQ:OTLK) announced that Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics, will present in a fireside chat at the virtual BTIG Ophthalmology Day on November 29, 2022 at 12:30 PM ET. In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative with interest.
Todos Medical Ltd. (OTCQB:TOMDF) announced that company representatives will attend World Antiviral Congress 2022, taking place between 28th of November, 2022 – 1st of December, 2022 at Loews Coronado Bay Resort, San Diego.
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) announced that the U.S. Food & Drug Administration has responded that a Type C meeting would be recommended to discuss the overall development plan and the latest revised endpoints for Revive’s Phase 3 clinical trial of Bucillamine. The FDA has now requested additional information, which would include clinical data, for them to agree on the study’s revised endpoints. Revive plans to go over with the FDA the overall development plan for Bucillamine in COVID-19 and further review the Pre-Dose selection data that would support the appropriate endpoints. Additional secondary endpoints may include the time to the polymerase chain reaction resolution, clinical outcome (death or hospitalization), disease severity, supplemental oxygen use, and progression of COVID-19. Should the FDA agree with the revised protocol, the Data Safety Monitoring Board will then review the completed Post-Dose selection data of approximately 500 subjects in the context of the new primary endpoint. The DSMB may recommend continuing the study if there is a trend toward achieving statistical significance, halting the study early due to statistical significance likely not going to be met, or halting the study early due to positive efficacy showing statistical significance.
AmeraMex International (OTCQB:AMMX) has rescheduled its conference call to review the company’s financials for the third quarter and nine-month period ending September 30, 2022. A news release with dial-in information for the company’s conference call will be issued “as soon as possible,” according to a release.